OneSkin

Is Amazon the destination for Longevity start-ups?

Latest articles

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...
OneSkin

Longevity is fast becoming the distinct investment category we predicted; from apps to xenotransplantation, some $4bn has been poured into finding solutions for driving lifespan and healthspan, according to Laura Deming, founder of the Longevity Fund [1].

Longevity.Technology: The Big Four of the new golden age of tech (Apple, Facebook, Amazon and Google) are all investors in longevity research. Google, under the umbrella of parent company Alphabet Inc’s anti-aging subsidiary Calico, is responsible for approximately half of the $4bn, however Amazon and its founder and chief executive Jeff Bezos have been increasingly active in the space. We’ve already identified that Amazon’s Alexa will be a key platform for independent living. As M&A will hot-up, will Amazon be the destination for many Longevity start-ups? We decided to take a look at where else Amazon is active. 

Back in 2013, Jeff Bezos was already hinting at a change of focus: “If your customer base is aging with you, then eventually you are going to become obsolete or irrelevant. You need to be constantly figuring out who are your new customers and what are you doing to stay forever young [2].”

And Bezos has done just that; Amazon’s retail dominance seems unshakeable (despite calls for investigations into its taxes [3] and regulation of its dominance [4]), but Bezos is not a man to rest on his laurels. In 2017 Amazon invested in Grail Inc, a Silicon Valley start-up that had, the year before, planted itself in the preventative medicine market with a position that the “cure” for most cancers won’t be a new drug, but news tests that will catch tumours at an early stage when they can still be successfully treated. Grail plans to do this by using “high-intensity” DNA sequencing to probe and screen blood samples for genetic material and biomarkers given-off by hidden tumours. Of course, this will require a huge amount of data processing and storage, which could be music to the ears of Amazon Web Services.

According to a 2015 report, by 2025, an anticipated 100 million and 2 billion human genomics could be sequenced [5] requiring an incredible amount of computing resources (exceeding those of YouTube and Twitter) and making a serious return for investors. By 2017 Grail had raised $1.1 billion, a sum that put it among the top three most heavily funded private biotech companies, according to EvaluatePharma [6] and clinical trials are currently enrolling.

As well as investing Amazon’s money, Bezos also put his hand in his own pocket, investing millions in  Unity Biotechnology, a start-up that declares its mission to be making the “debilitating consequences of aging as uncommon as polio [7].” Along with Baillie Gifford, Venrock, ARCH Venture Capital, Mayo Clinic and WuXi Pharmaceuticals, Bezos raised $116 million in Series B financing for Unity Biotech. Their research focuses in particular on senescent cells — older cells that have stopped the normal process of cell division. Senescent cells are one of the causes of the onset of the diseases associated with aging and being able to rejuvenate them, or controlling their effect on various body processes is one of the holy grails of anti-aging research. Unity Bio has already shown in animal models that by a selective removal of senescent cells, it is possible to reverse or prevent several diseases linked to aging, including kidney diseases, osteoarthritis, atherosclerosis and several eye diseases.

Amazon has also backed Juno Therapeutics, which was acquired for $9 billion last year by Celgene (who were in turn acquired by Bristol-Myers Squibb); however, Bezos spotted this company’s potential back in 2014 when his venture capital arm Bezos Expeditions, was an early investor. An IPO success story, Juno Therapeutics made headlines in the biotech world for its breakthrough discoveries in cancer medicine, notably an exciting new type of treatment called chimeric antigen receptor T-cell therapy, or CAR-T, which works by reprogramming previously-extracted T-cells so they can identify cancer. Once re-purposed, the cells are are infused back into the patient’s body, and set about eliminating the cancerous cells. Juno’s liso-cel, also called JCAR017, outperformed other similar therapies already on the market (Yescarta and Kymriah) in both efficacy and safety, earning itself the “best-in-class” label [8] and paying back investors’ confidence.

More recently, in 2018, Bezos Expeditions made a $15 million investment in Mindstrong Health’s Series B funding stage. Mindstrong Health’s mission is to “connect patients and providers with continuous, objective measures of cognition and mood giving patients agency in their care and providers the confidence that they can notice the early signs of mental health deterioration [9].” Given the focus on mental health and wellness, it is not surprising that the company is generating traction. According to MIT Technology Review, Mindstrong Health is “the smartphone app that can tell you’re depressed before you know it yourself [10].”

That’s not the only app or smart technology that Amazon have dallied with. Longevity.Technology has previous reported on a range of Alexa-based patient solutions, smart speakers that detect cardiac arrests and apps that improve healthspans for Alzheimer’s sufferers. Amazon has also linked with the NHS in the UK to allow users to access health information through the AI-powered voice assistant Alexa and new voice-activated applications under development include ones that manage health-improvement goals or handle blood-sugar readings. In June 2018, Amazon paid nearly $1bn for the online pharmacy PillPack [11], which has licences to supply prescription drugs across the US, a smart move as patients are beginning to expect the level of service and flexibility from healthcare that they get from online retailers.

Jeff Bezos has shown a keen eye for investment opportunities in the past. His spread of longevity investment over the last few years shows he can take his own advice, steering his portfolio away from the obsolete and towards the forever young.

Image: lev radin / Shutterstock.com

[1] https://www.ft.com/content/cbdc1cd0-8126-11e9-9935-ad75bb96c849
[2] https://abcn.ws/31BMmXT
[3] https://twitter.com/JoeBiden/status/1139188173131591685
[4] https://bit.ly/2EOz2FX
[5] https://www.nature.com/news/genome-researchers-raise-alarm-over-big-data-1.17912
[6] https://bit.ly/31BMmal
[7] https://bit.ly/33LMbKJ
[8] https://bit.ly/2BF2AVD
[9] https://mindstronghealth.com/about/
[10] https://bit.ly/2Eo6Z3a
[11] https://tcrn.ch/2lHxGUA

 

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
OneSkin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

NAD+ and metformin: AgelessRx’s anti-aging platform

Personalised longevity medicine is the top goal for AgelessRx. In November we spoke to Anar Isman, the Co-founder & CEO of AgelessRx, about PEARL, the...
Apollo Neuro

Related articles

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

Elastrin limbers up for success with Kizoo funding boost

Kizoo provides seed funding for Elastrin Therapeutics to develop ground-breaking new technology capable of reversing tissue and organ calcification. It was announced today that Elastrin,...

Targeting longevity risk management

Vesttoo harnesses the power of AI for data-driven management of longevity risk. Israel-based start-up Vesttoo has developed a set of data-driven risk management solutions for...

AgeX and LyGenesis to negotiate merger agreement

The biotech merger between AgeX and LyGenesis will neaten-up Juvenescence's portfolio. AgeX Therapeutics, a biotech developing therapeutics for human aging and cell regeneration, and LyGenesis,...
OneSkin